1. DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity
   Henning Willers et al, 2015, Seminars in Radiation Oncology CrossRef
2. PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction
   Matthew Trendowski, 2015, Pharmacological Research CrossRef
3. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
   Suqin He et al, 2014, Investigational New Drugs CrossRef
4. Harnessing mitochondrial metabolism and drug resistance in non-small cell lung cancer and beyond by blocking heat-shock proteins
   Beatrice Parma et al, 2022, Drug Resistance Updates CrossRef
5. Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review)
   Biaoxue Rong et al, 2017, International Journal of Oncology CrossRef
6. Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity
   Kirsten Lauber et al, 2015, Cancer Letters CrossRef
7. TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation
   Younghyun Lee et al, 2017, Molecular Cancer Therapeutics CrossRef
8. Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein
   Peter J. Ferguson et al, 2018, Journal of Pharmacology and Experimental Therapeutics CrossRef
9. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy
   Huizi Keiko Li et al, 2016, Journal of Radiation Research CrossRef
10. Heat Shock Proteins in Non-Small-Cell Lung Cancer—Functional Mechanism
    Guanyu Zhou et al, 2023, Frontiers in Bioscience-Landmark CrossRef
11. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators
    Şule Kale et al, 2020, Naunyn-Schmiedeberg's Archives of Pharmacology CrossRef
12. 8.2.2 DNA Damage and Repair by Particle Beam
    Atsushi Shibata, 2019, RADIOISOTOPES CrossRef
13. Hsp90: A New Player in DNA Repair?
    Rosa Pennisi et al, 2015, Biomolecules CrossRef
14. PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond
    Sameh Saber et al, 2024, Frontiers in Pharmacology CrossRef
15. Ganetespib selectively sensitizes cancer cells for proximal and distal spread-out Bragg peak proton irradiation
    Simon Deycmar et al, 2022, Radiation Oncology CrossRef
16. Drugging the Cancers Addicted to DNA Repair
    Jac A. Nickoloff et al, 2017, JNCI: Journal of the National Cancer Institute CrossRef
17. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining
    Younghyun Lee et al, 2016, Radiotherapy and Oncology CrossRef
18. First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile
    Giovanna Speranza et al, 2018, Investigational New Drugs CrossRef
19. Strategies to Enhance Radiosensitivity to Heavy Ion Radiation Therapy
    Younghyun Lee et al, 2018, International Journal of Particle Therapy CrossRef